Find a Clinical Trial

Find a Clinical Trial

Search by practice name, trial titles, indicators and specific disease types.

Gall Bladder Cancer

Clinical Trial at: OHC - Cincinnati

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

601 Ivy Gateway
Cincinnati, OH 45245
P: (888) 649-4800

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: OHC - Cincinnati

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

4350 Malsbary Road, 1st Floor
Cincinnati, OH 45242
P: (888) 649-4800

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: OHC - Cincinnati

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

4777 E. Galbraith Rd, Suite 320
Cincinnati, OH 45236
P: (888) 649-4800

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: OHC - Cincinnati

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

3301 Mercy Health Blvd, Suite 100
Cincinnati, OH 45211
P: (888) 649-4800

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Texas Oncology - Austin

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

4101 James Casey St, Suite 100
Austin, TX 78745
P: (512) 447-2202

More Details View Practice Page

Gall Bladder Cancer

Clinical Trial at: Texas Oncology - Austin

A Phase 3 Multicenter, Open-Label, Randomized, Controlled Study of Oral Infigratinib versus Gemcitabine with Cisplatin in Subjects with Advanced/Metastatic or Inoperable Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations: The PROOF Trial (QBGJ398-301)

  • Details

ClinicalTrials.gov ID: NCT03773302
Diagnosis Type: Gall Bladder Cancer
USOR Number: 18264

  • Practice Details

901 W 38th Street, Suite 200
Austin, TX 78705
P: (512) 421-4100

More Details View Practice Page